| Literature DB >> 32712804 |
Jun Zhang1, Min Lian1, Bo Li1, Lixia Gao2, Toshihiro Tanaka3, Zhengrui You1, Yiran Wei1, Yong Chen1, Yikang Li1, You Li1, Bingyuan Huang1, Ruqi Tang1, Qixia Wang1, Qi Miao1, Yanshen Peng1, Jingyuan Fang1, Zhexiong Lian4,5,6, Kazuichi Okazaki3, Xiao Xiao7, Weici Zhang8, Xiong Ma9.
Abstract
IgG4-related disease (IgG4-RD) is characterized by intense infiltration of IgG4-positive plasma cells in affected organs. However, the mechanisms acting in the immune responses in IgG4-RD are not fully understood. The aim of this study was to dissect the mechanism underlying the immunoglobulin class switch in IgG4-RD by addressing the crosstalk between IL-35-producing and Th9 cells. The expression level of IL-35 was examined in plasma samples from patients with hepatobiliary and/or pancreatic manifestations of IgG4-RD. Our data demonstrate that IgG4-RD patients exhibit significantly high-level productions of IL-35 as compared to disease and healthy controls. We detected the two subunits of IL-35, EBI3 and IL-12p35, in the two major affected organs, liver and pancreatic tissue, from IgG4-RD. The EBI3- and IL-12p35-positive cells were significantly higher in affected organs in IgG4-RD as compared to disease controls. The colocalization of EBI3 with CD19 and CD38, markers for B cells, suggest the presence of IL-35-producing B cells in affected organs in IgG4-RD. The effects of IL-35 in Th9 differentiation and IL-9 in production of immunoglobulin were then assessed. Surprisingly, IL-35 treatment promoted naïve CD4 T cell differentiating towards Th9 cells through IRF4 signaling. As a consequence, IL-9 secreted by Th9 cells promoted the differentiation of plasma cells and production of IgG1 and IgG4, predominantly IgG4. In conclusion, our data demonstrate that IL-35 actively participates in the process of inflammation and plays an important role in Th9 differentiation resulting in an immunoglobulin class switch towards IgG4.Entities:
Keywords: IgG4-related disease; Interleukin-35; Th9 cell
Year: 2020 PMID: 32712804 DOI: 10.1007/s12016-020-08803-8
Source DB: PubMed Journal: Clin Rev Allergy Immunol ISSN: 1080-0549 Impact factor: 8.667